Anti-Human HLA-DR PerCP-Cyanine5.5


The LN3 monoclonal antibody specifically reacts with the human leukocyte antigen-DR (HLA-DR), a MHC class II heterodimeric surface glycoprotein. HLA-DR is expressed on the antigen presenting surfaces of monocytes, macrophages, dendritic cells, activated T cells, and B cells. It is integral to peptide presentation to CD4+ T cells. Tonabersat

Clone
LN3
Format:
PerCP-Cyanine5.5
Applications
FC
Reactivity
Human
Isotype:
Mouse IgG2b, kappa
Research Interest:
Cell Type: , ,
Preperation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Norton, A. J., & Isaacson, P. G. (1987). Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. The American journal of pathology128(2), 225.

Hua, Z. X., Tanaka, K. E., Tazelaar, H. D., Myers, J., Markowitz, G. S., & Borczuk, A. C. (1998). Immunoreactivity for LN2 and LN3 distinguishes small cell carcinomas from non-small cell carcinomas in the lung. Human pathology,29(12), 1441-1446.

Ioachim, H. L., Pambuccian, S. E., Hekimgil, M., Giancotti, F. R., & Dorsett, B. H. (1996). Lymphoid monoclonal antibodies reactive with lung tumors: diagnostic application. The American journal of surgical pathology20(1), 64-71.

MED: 19043995

Related Post